Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets

Recently, Beilu Pharmaceutical received the Drug Registration Certificate for two sizes (0.375mg and 0.75mg) of Pramipexole Dihydrochloride Sustained-release Tablets (Pramipexole) from the National Medical Products Administration (NMPA).

Pramipexole is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults, that is, during the course of the disease, including later stages, when the effect of levodopa gradually wears off or changes and fluctuates (end-of-dose phenomenon or "on-off" fluctuations), the product may be used alone (without L-dopa) or in combination with L-dopa.

In recent years, the Company has continued to increase its investment in research and development. On the basis of deep cultivation of contrast agents, the company aims to solve clinical needs, focusing on cardiovascular, digestive, neuropsychiatric, endocrine and other fields. Jiuwei Zhenxin Granule is the company's blockbuster product in the field of psychoneurotics. This pramexol hydrochloride sustained-release tablet has obtained the "Drug Registration Certificate", which further enriches the company's product layout in this field.